These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8315572

  • 1. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M, Rudén U, Birx D, Loomis L, Redfield R, Lövgren K, Akerblom L, Sandström E, Wahren B.
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [Abstract] [Full Text] [Related]

  • 2. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP.
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [Abstract] [Full Text] [Related]

  • 3. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A, Gluckman JC, Rochat H, Montagnier L, Bahraoui E.
    J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
    [Abstract] [Full Text] [Related]

  • 4. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G.
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [Abstract] [Full Text] [Related]

  • 5. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
    Wolf H, Warren RQ, Stunz GW, Shuler KR, Kanda P, Kennedy RC.
    Mol Immunol; 1992 Nov; 29(7-8):989-98. PubMed ID: 1378936
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
    Salmon-Céron D, Excler JL, Sicard D, Blanche P, Finkielstzjen L, Gluckman JC, Autran B, Matthews TJ, Meignier B, Kieny MP.
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
    [Abstract] [Full Text] [Related]

  • 7. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
    Ronco J, Dedieu JF, Marie FN, Pinter A, Kaczorek M, Girard M.
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
    [Abstract] [Full Text] [Related]

  • 8. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD.
    Proc Natl Acad Sci U S A; 1993 Mar 01; 90(5):1882-6. PubMed ID: 8446603
    [Abstract] [Full Text] [Related]

  • 9. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD.
    Proc Natl Acad Sci U S A; 1993 Mar 15; 90(6):2443-7. PubMed ID: 8460155
    [Abstract] [Full Text] [Related]

  • 10. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, Lewis GK.
    AIDS Res Hum Retroviruses; 1994 Apr 15; 10(4):371-81. PubMed ID: 8068416
    [Abstract] [Full Text] [Related]

  • 11. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A, Sjölander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein B, Olofsson S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul 15; 12(3):213-20. PubMed ID: 8673525
    [Abstract] [Full Text] [Related]

  • 12. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
    Wahren B, Bratt G, Persson C, Levén B, Hinkula J, Gilljam G, Nordlund S, Eriksson L, Volvovitz F, Broliden PA.
    J Acquir Immune Defic Syndr (1988); 1994 Mar 15; 7(3):220-9. PubMed ID: 7906300
    [Abstract] [Full Text] [Related]

  • 13. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
    Gorse GJ, Frey SE, Newman FK, Belshe RB.
    J Clin Microbiol; 1992 Oct 15; 30(10):2606-12. PubMed ID: 1400960
    [Abstract] [Full Text] [Related]

  • 14. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.
    McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD.
    J Infect Dis; 1994 Jan 15; 169(1):41-7. PubMed ID: 8277196
    [Abstract] [Full Text] [Related]

  • 15. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
    Loomis LD, Deal CD, Kersey KS, Burke DS, Redfield RR, Birx DL.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep 01; 10(1):13-26. PubMed ID: 7544225
    [Abstract] [Full Text] [Related]

  • 16. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR, Strick N, Li YY, Jiang S.
    AIDS Res Hum Retroviruses; 1993 Dec 01; 9(12):1195-208. PubMed ID: 8142138
    [Abstract] [Full Text] [Related]

  • 17. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
    Höglund S, Akerblom L, Ozel M, Villacres M, Eriksson M, Gelderblom HR, Arthur L, Morein B.
    Viral Immunol; 1990 Dec 01; 3(3):195-206. PubMed ID: 2257052
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A, Gluckman JC, Montagnier L, Bahraoui E.
    J Virol; 1993 Mar 01; 67(3):1693-7. PubMed ID: 7679751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.